Dr Lalchandani Labs Ltd
₹ 11.4
-4.67%
30 Apr
- close price
About
Incorporated in 2011, Dr. Lalchandani Labs Ltd is in the business of running laboratories
for pathological investigations[1]
Key Points
- Market Cap ₹ 4.95 Cr.
- Current Price ₹ 11.4
- High / Low ₹ 28.9 / 0.00
- Stock P/E 5.75
- Book Value ₹ 22.4
- Dividend Yield 0.00 %
- ROCE -2.68 %
- ROE -8.23 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 0.51 times its book value
Cons
- Promoter holding has decreased over last quarter: -3.60%
- The company has delivered a poor sales growth of -1.77% over past five years.
- Company has a low return on equity of -4.80% over last 3 years.
- Company has high debtors of 357 days.
- Working capital days have increased from 271 days to 402 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Upcoming result date: tomorrow
Profit & Loss
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 2.79 | 5.26 | 6.10 | 9.78 | 11.28 | 5.04 | 4.81 | 4.21 | |
| 2.17 | 4.06 | 4.84 | 7.54 | 8.81 | 4.95 | 4.59 | 2.63 | |
| Operating Profit | 0.62 | 1.20 | 1.26 | 2.24 | 2.47 | 0.09 | 0.22 | 1.58 |
| OPM % | 22.22% | 22.81% | 20.66% | 22.90% | 21.90% | 1.79% | 4.57% | 37.53% |
| 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 1.40 | 0.24 | |
| Interest | 0.16 | 0.14 | 0.18 | 0.35 | 0.60 | 0.99 | 0.38 | 0.33 |
| Depreciation | 0.13 | 0.35 | 0.42 | 0.52 | 0.59 | 0.66 | 0.62 | 0.57 |
| Profit before tax | 0.36 | 0.72 | 0.66 | 1.37 | 1.28 | -1.56 | 0.62 | 0.92 |
| Tax % | 25.00% | 26.39% | 28.79% | 26.28% | 28.12% | 0.00% | 0.00% | |
| 0.26 | 0.53 | 0.47 | 1.01 | 0.93 | -1.56 | 0.62 | 0.86 | |
| EPS in Rs | 0.89 | 1.22 | 1.08 | 2.33 | 2.15 | -3.60 | 1.43 | 1.99 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -2% |
| 3 Years: | -21% |
| TTM: | -23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 226% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | -33% |
| 1 Year: | -45% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | -5% |
| Last Year: | -8% |
Balance Sheet
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.93 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 |
| Reserves | 0.40 | 3.73 | 4.21 | 5.22 | 6.15 | 4.59 | 5.21 | 5.36 |
| 1.88 | 0.90 | 1.76 | 4.04 | 5.15 | 6.40 | 3.48 | 3.63 | |
| 1.00 | 1.18 | 1.63 | 1.61 | 2.49 | 2.40 | 1.97 | 2.05 | |
| Total Liabilities | 6.21 | 10.14 | 11.93 | 15.20 | 18.12 | 17.72 | 14.99 | 15.37 |
| 2.06 | 3.28 | 3.47 | 5.24 | 5.75 | 5.39 | 3.99 | 3.79 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.41 | 0.27 |
| 3.91 | 6.62 | 8.22 | 9.72 | 12.13 | 12.09 | 10.59 | 11.31 | |
| Total Assets | 6.21 | 10.14 | 11.93 | 15.20 | 18.12 | 17.72 | 14.99 | 15.37 |
Cash Flows
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|
| 0.58 | -0.45 | -0.10 | 1.19 | 2.01 | 0.00 | -0.22 | |
| -1.29 | -1.95 | -0.53 | -2.26 | -1.53 | -0.20 | 1.00 | |
| 1.57 | 3.51 | 0.85 | 1.71 | 0.16 | -0.23 | -1.59 | |
| Net Cash Flow | 0.85 | 1.12 | 0.23 | 0.64 | 0.64 | -0.43 | -0.81 |
Ratios
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 149.14 | 126.99 | 199.25 | 148.54 | 136.55 | 359.93 | 356.65 |
| Inventory Days | 167.03 | 233.36 | 158.70 | 68.75 | 191.07 | 458.51 | 255.15 |
| Days Payable | 426.86 | 406.89 | 355.48 | 97.06 | 175.15 | 404.21 | 217.94 |
| Cash Conversion Cycle | -110.69 | -46.54 | 2.47 | 120.23 | 152.47 | 414.23 | 393.86 |
| Working Capital Days | 168.76 | 170.70 | 209.43 | 132.86 | 123.93 | 287.51 | 402.18 |
| ROCE % | 12.14% | 8.72% | 14.40% | 12.87% | -3.68% | -2.68% |
Documents
Announcements
-
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
3h - Company states it is not a 'Large Corporate' per SEBI; borrowings under Rs. 1000 crore as of March 31, 2025.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
3h - Dr Lalchandani Labs confirms not a Large Corporate as of 31-Mar-2025 per SEBI norms.
-
Board Meeting Intimation for Consider And Approve The Audited Financial Statements Of The Company For The Financial Year Ending On March 2025
25 Apr - Board meeting on May 1, 2025, to approve audited financial results for FY and H1 ending March 31, 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Apr - Compliance certificate for the quarter ended March 31, 2025
- Closure of Trading Window 28 Mar
Business Overview:[1][2][3]
DLLL is a NABL accredited company with 5 Self-sufficient Labs and 15 collection centers across Delhi/NCR. It is empaneled for CGHS (South, North and East Block), DJB, MCD, DDA etc. and provides diagnostic and related healthcare tests and services. Company owns, runs laboratories for carrying out pathological investigations of various branches of Bio-Chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Virology, Cytology, other pathological Investigations and Immunoassay, Immuno-Histochemistry, Molecular Pathology, DNA & Genetic Testing etc.